NCT04382170View on ClinicalTrials.gov

Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Delirium

Interventions

DRUG

Dexmedetomidine sublingual film

Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.

Sponsors

Collaborators (1)

BioXcel Therapeutics Inc

All Listed Sponsors

collaborator

BioXcel Therapeutics Inc

INDUSTRY

lead

Jeff C. Huffman, MD

OTHER

NCT04382170 - Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy | Biotech Hunter | Biotech Hunter